ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 1181

Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Abstract Number: 1402

Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Abstract Number: 1779

Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications
Abstract Number: 0975

Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage
Abstract Number: 0267

Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Abstract Number: 0821

Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
Abstract Number: 0876

Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials
Abstract Number: 1703

Gender Equity in Academic Rheumatology – Is There a Gender Gap at European Rheumatology Congresses?
Abstract Number: 0034

Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis
Abstract Number: 1580

Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events
Abstract Number: 0301

Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus
Abstract Number: 1862

Genetic Influences on Occurrence of Axial Spondyloarthritis (axSpA) in First-degree Relatives During a Prospective Study Lasting 35 Years
Abstract Number: 0494

Genetic-epigenetic Interaction and the Relationship Between DNA Methylation Patterns and Disease Activity in a Longitudinal Cohort of Lupus Patients
Abstract Number: 1669

Genetics of Age at Diagnosis in Systemic Lupus Erythematosus
Abstract Number: 0982

Genetics of Avascular Necrosis in Children and Adults with Systemic Lupus Erythematosus
Abstract Number: 1954

Genome-wide Association Study of Sjögren’s Syndrome Identifies Ten New Risk Loci
Abstract Number: 0283

Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
Abstract Number: 0661

Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Abstract Number: 0500

Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis
Abstract Number: 2037

Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts
Abstract Number: 0086

Geographic Distribution of Eosinophilic Fasciitis Cases in Massachusetts and Associated Environmental Triggers
Abstract Number: 0043

Geographical Disparity in Rheumatoid Arthritis Disease Burden Independent of Race/Ethnicity
Abstract Number: 0005

Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists
Abstract Number: 0238

Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
Abstract Number: 1257

Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
Abstract Number: 1932

Giant Cell Arteritis – the Relationship Between the Extensiveness of Vasculitis and the Clinical Presentation
Abstract Number: 1077

Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Abstract Number: 1224

Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Abstract Number: 0129

Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
Abstract Number: 0109

Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Abstract Number: 1682

Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Abstract Number: 0578

Going Digital Due to COVID 19 Crisis: A Rapid Reorganisation of Medication Clinics
Abstract Number: 0657

Gout and Heart Failure in the US
Abstract Number: 0681

Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Abstract Number: 1573

Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Abstract Number: 0600

Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation
Abstract Number: 0673

Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
Abstract Number: 0667

Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Abstract Number: 0853

Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
Abstract Number: 0259

Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
Abstract Number: 0888

Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naïve Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study
Abstract Number: 0908

Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
Abstract Number: 0332

Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Abstract Number: 0367

Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
Abstract Number: 1349

Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Abstract Number: 0370

Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1
Abstract Number: 1344

Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
Abstract Number: 1310

Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
Abstract Number: 1971

Gut Microbiome Transplantation from MRL/MpJ Mice Prevents Post-Traumatic Osteoarthritis in C57BL6/J Mice

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].